MiNK Therapeutics

MiNK Therapeutics

MiNK Therapeutics operates as a clinical-stage biotechnology company focused on engineering invariant natural killer T (iNKT) cell therapies. iNKT cells are a rare lymphocyte population that bridge innate and adaptive immunity, offering the potential to treat solid tumors that have evaded first-generation CAR-T approaches. The company's lead asset, agenT-797, is an unmodified allogeneic iNKT cell therapy currently in clinical evaluation for solid tumors and acute respiratory distress syndrome, 2023). Unlike patient-specific autologous therapies requiring vein-to-vein logistics, MiNK's off-the-shelf model aims to deliver a scalable, readily available product — a manufacturing and cost advantage that shapes its strategic identity. The firm's strategy centers on deploying its iNKT platform across oncology and immune-mediated diseases, with an emphasis on solid tumors where other cell therapies have struggled due to tumor microenvironment suppression and antigen escape. The company has also explored applications in infectious disease-related immune dysregulation, evidenced by clinical work in ARDS, and maintains a pipeline of next-generation engineered iNKT cell constructs. Manufacturing is conducted through in-house GMP facilities, which supports supply chain independence and positions MiNK to control cost of goods as programs mature toward later-stage trials. MiNK was formed through a contribution of assets from Agenus Inc., the immunotherapy company led by Garo Armen, and trades on the Nasdaq under the ticker NKTX (per the firm's official communications, 2021). The relationship with Agenus provides MiNK access to a broader research apparatus, including antibody discovery capabilities that can generate tumor-targeting moieties for future engineered iNKT programs. In September 2021, MiNK completed an initial public offering, raising approximately $40 million to fund clinical development. The firm does not publicly disclose assets under management, investment portfolio, or principal investment personnel beyond the scientific leadership and board of directors disclosed in its regulatory filings. Structurally, MiNK is a rare publicly traded pure-play dedicated to iNKT cell therapy — a specialization that sets it apart from broader multi-modality biotechs. Its relationship with Agenus provides a pipeline of antibody targeting agents that could be co-opted for next-generation iNKT cell engagers, creating a differentiated R&D flywheel. The company's governance structure, with concentrated insider ownership from Agenus, aligns research priorities but also concentrates strategic control, a dynamic relevant to allocators assessing alignment of interest in the biotech space.